Charisma Hehakaya
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Charisma Hehakaya has a total of 22 co-authors. Here are the top co-authors by number of shared publications:
Diederick E. Grobbee
Utrecht University, Utrecht, the Netherlands
4 shared publicationsEllen H. M. Moors
Utrecht University
4 shared publicationsHelena M. Verkooijen
Division of Imaging & Oncology, University Medical Center Utrecht, The Netherlands
4 shared publicationsAnkur M. Sharma
University of Tennessee Health Science Center, Memphis, Tennessee
1 shared publication- Ben G. L. Vanneste
Department of Radiation Oncology (MAASTRO), GROW - School for Oncology and Developmental Biology, Maastricht University Medical Center+, Maastricht, the Netherlands
1 shared publication - Diederick E. Grobbee
Julius Center for Health Sciences and Primary Care, University Medical Center Utrecht, Universiteitsweg 100, 3584 CG Utrecht, The Netherlands
1 shared publication
Latest Publications
- Open Access
- 1 June 2023
- Published by Elsevier in Clinical and Translational Radiation Oncology
- Vol. 41, 100644
Realizing the value of complex medical technology: Demonstrating cost-effectiveness is not enough
- 1 June 2023
- Published by Elsevier in Clinical and Translational Radiation Oncology
- Vol. 41, 100644
Open AccessRealizing the value of complex medical technology: Demonstrating cost-effectiveness is not enough
- Open Access
- 15 May 2023
- Published by Taylor & Francis in Innovation
- Vol. 27 (1) , 74-95
Institutionalisation of convergent medical innovation: an empirical study of the MRI-guided linear accelerator in the Netherlands and the United States
Although convergence is a major trend in the development of medical innovations, the implications of the institutionalisation of convergent innovation are understudied. This paper explores how the institutionalisation of convergent innovation affects the organisation of health care, by using operational domains and categories of the Non-adoption, Abandonment, Scale-up, Spread and Sustainability (NASSS) and the Institutional Readiness (IR) approach respectively. We use an illustrative comparative case study on the institutionalisation of MRI-guided linear accelerator (MR-Linac) technology in the Netherlands and the United States. Empirically, we conducted 66 interviews with different professionals in the health care system around MR-Linac. The findings show that institutionalisation of convergent innovation affects the organisation of health care by: changing the traditional organisation of solving a medical problem, thereby transforming and reorganising work in the health care environment, providing opportunities for individual user development, collective action and cross-sectoral developments, and requiring the additional work of evaluating convergent innovation, including administrative tasks, innovation and research activities within and across institutions. The insights offered are also relevant for understanding convergence in the medical field, and for rethinking medical innovation in general.
- 15 May 2023
- Published by Taylor & Francis in Innovation
- Vol. 27 (1) , 74-95
Open AccessInstitutionalisation of convergent medical innovation: an empirical study of the MRI-guided linear accelerator in the Netherlands and the United States
Although convergence is a major trend in the development of medical innovations, the implications of the institutionalisation of convergent innovation are understudied. This paper explores how the institutionalisation of convergent innovation affects the organisation of health care, by using operational domains and categories of the Non-adoption, Abandonment, Scale-up, Spread and Sustainability (NASSS) and the Institutional Readiness (IR) approach respectively. We use an illustrative comparative case study on the institutionalisation of MRI-guided linear accelerator (MR-Linac) technology in the Netherlands and the United States. Empirically, we conducted 66 interviews with different professionals in the health care system around MR-Linac. The findings show that institutionalisation of convergent innovation affects the organisation of health care by: changing the traditional organisation of solving a medical problem, thereby transforming and reorganising work in the health care environment, providing opportunities for individual user development, collective action and cross-sectoral developments, and requiring the additional work of evaluating convergent innovation, including administrative tasks, innovation and research activities within and across institutions. The insights offered are also relevant for understanding convergence in the medical field, and for rethinking medical innovation in general.
- Open Access
- 25 May 2022
- Published by Elsevier in Advances in Radiation Oncology
- Vol. 7 (5) , 100953
Implementation of Magnetic Resonance Imaging-Guided Radiation Therapy in Routine Care: Opportunities and Challenges in the United States
- 25 May 2022
- Published by Elsevier in Advances in Radiation Oncology
- Vol. 7 (5) , 100953
Open AccessImplementation of Magnetic Resonance Imaging-Guided Radiation Therapy in Routine Care: Opportunities and Challenges in the United States
- 16 May 2022
- Published by Springer Nature in Nature Human Behaviour
- Vol. 6 (7) , 902-903
Academic institutions need to do more to support first-generation students
- 16 May 2022
- Published by Springer Nature in Nature Human Behaviour
- Vol. 6 (7) , 902-903
Academic institutions need to do more to support first-generation students
- Open Access
- 1 August 2021
- Published by Elsevier in Radiotherapy and Oncology
- Vol. 161, 74-82
Early health economic analysis of 1.5 T MRI-guided radiotherapy for localized prostate cancer: Decision analytic modelling
- 1 August 2021
- Published by Elsevier in Radiotherapy and Oncology
- Vol. 161, 74-82
Open AccessEarly health economic analysis of 1.5 T MRI-guided radiotherapy for localized prostate cancer: Decision analytic modelling
- Open Access
- 8 November 2020
- Published by Springer Nature in European Journal of Nuclear Medicine and Molecular Imaging
- Vol. 48 (8) , 2325-2328
177Lu-PSMA for advanced prostate cancer: are we ready to play big?
- 8 November 2020
- Published by Springer Nature in European Journal of Nuclear Medicine and Molecular Imaging
- Vol. 48 (8) , 2325-2328
Open Access177Lu-PSMA for advanced prostate cancer: are we ready to play big?
- Open Access
- 2 September 2020
- Published by Frontiers Media SA in Frontiers in Oncology
- Vol. 10
Problems and Promises of Introducing the Magnetic Resonance Imaging Linear Accelerator Into Routine Care: The Case of Prostate Cancer
The new radiotherapy high field, 1.5 Tesla MRI-guided linear accelerator (MR-Linac) is being clinically introduced. Sensing and evaluating opportunities and barriers at an early stage will facilitate its eventual scale-up. This study investigates the opportunities and barriers to the implementation of MR-Linac into prostate cancer care based on 43 semi-structured interviews with Dutch oncology care professionals, hospital and division directors, patients, payers and industry. The analysis was guided by the Non-adoption, Abandonment, Scale-up, Spread, and Sustainability framework of new medical technologies and services. Opportunities included: the acquirement of (1) advanced MRI-guided radiotherapy technology with (2) the potential for improved patient outcomes and (3) economic benefits, as well as (4) professional development and (5) a higher hospital quality profile. Barriers included: (1) technical complexities, (2) substantial staffing and structural investments, (3) the current lack of empirical evidence of clinical benefits, (4) professional silos, and (5) the presence of patient referral patterns. While our study confirms the expected technical and clinical prospects from the literature, it also reveals economic, organizational, and socio-political challenges.
- 2 September 2020
- Published by Frontiers Media SA in Frontiers in Oncology
- Vol. 10
Open AccessProblems and Promises of Introducing the Magnetic Resonance Imaging Linear Accelerator Into Routine Care: The Case of Prostate Cancer
The new radiotherapy high field, 1.5 Tesla MRI-guided linear accelerator (MR-Linac) is being clinically introduced. Sensing and evaluating opportunities and barriers at an early stage will facilitate its eventual scale-up. This study investigates the opportunities and barriers to the implementation of MR-Linac into prostate cancer care based on 43 semi-structured interviews with Dutch oncology care professionals, hospital and division directors, patients, payers and industry. The analysis was guided by the Non-adoption, Abandonment, Scale-up, Spread, and Sustainability framework of new medical technologies and services. Opportunities included: the acquirement of (1) advanced MRI-guided radiotherapy technology with (2) the potential for improved patient outcomes and (3) economic benefits, as well as (4) professional development and (5) a higher hospital quality profile. Barriers included: (1) technical complexities, (2) substantial staffing and structural investments, (3) the current lack of empirical evidence of clinical benefits, (4) professional silos, and (5) the presence of patient referral patterns. While our study confirms the expected technical and clinical prospects from the literature, it also reveals economic, organizational, and socio-political challenges.
- Open Access
- 26 May 2020
- Published by Springer Nature in European Radiology
- Vol. 30 (10) , 5525-5532
Implementation of artificial intelligence (AI) applications in radiology: hindering and facilitating factors
Objective: The objective was to identify barriers and facilitators to the implementation of artificial intelligence (AI) applications in clinical radiology in The Netherlands. Materials and methods: Using an embedded multiple case study, an exploratory, qualitative research design was followed. Data collection consisted of 24 semi-structured interviews from seven Dutch hospitals. The analysis of barriers and facilitators was guided by the recently published Non-adoption, Abandonment, Scale-up, Spread, and Sustainability (NASSS) framework for new medical technologies in healthcare organizations. Results: Among the most important facilitating factors for implementation were the following: (i) pressure for cost containment in the Dutch healthcare system, (ii) high expectations of AI’s potential added value, (iii) presence of hospital-wide innovation strategies, and (iv) presence of a “local champion.” Among the most prominent hindering factors were the following: (i) inconsistent technical performance of AI applications, (ii) unstructured implementation processes, (iii) uncertain added value for clinical practice of AI applications, and (iv) large variance in acceptance and trust of direct (the radiologists) and indirect (the referring clinicians) adopters. Conclusion: In order for AI applications to contribute to the improvement of the quality and efficiency of clinical radiology, implementation processes need to be carried out in a structured manner, thereby providing evidence on the clinical added value of AI applications. Key Points: • Successful implementation of AI in radiology requires collaboration between radiologists and referring clinicians. • Implementation of AI in radiology is facilitated by the presence of a local champion. • Evidence on the clinical added value of AI in radiology is needed for successful implementation.
- 26 May 2020
- Published by Springer Nature in European Radiology
- Vol. 30 (10) , 5525-5532
Open AccessImplementation of artificial intelligence (AI) applications in radiology: hindering and facilitating factors
Objective: The objective was to identify barriers and facilitators to the implementation of artificial intelligence (AI) applications in clinical radiology in The Netherlands. Materials and methods: Using an embedded multiple case study, an exploratory, qualitative research design was followed. Data collection consisted of 24 semi-structured interviews from seven Dutch hospitals. The analysis of barriers and facilitators was guided by the recently published Non-adoption, Abandonment, Scale-up, Spread, and Sustainability (NASSS) framework for new medical technologies in healthcare organizations. Results: Among the most important facilitating factors for implementation were the following: (i) pressure for cost containment in the Dutch healthcare system, (ii) high expectations of AI’s potential added value, (iii) presence of hospital-wide innovation strategies, and (iv) presence of a “local champion.” Among the most prominent hindering factors were the following: (i) inconsistent technical performance of AI applications, (ii) unstructured implementation processes, (iii) uncertain added value for clinical practice of AI applications, and (iv) large variance in acceptance and trust of direct (the radiologists) and indirect (the referring clinicians) adopters. Conclusion: In order for AI applications to contribute to the improvement of the quality and efficiency of clinical radiology, implementation processes need to be carried out in a structured manner, thereby providing evidence on the clinical added value of AI applications. Key Points: • Successful implementation of AI in radiology requires collaboration between radiologists and referring clinicians. • Implementation of AI in radiology is facilitated by the presence of a local champion. • Evidence on the clinical added value of AI in radiology is needed for successful implementation.